484 related articles for article (PubMed ID: 26512791)
21. Induced sarcoid-like reactions in patients with metastatic melanoma treated with dabrafenib and trametinib: a monocentric retrospective study.
Huynh S; Lheure C; Franck N; Goldman-Lévy G; Aractingi S; Dupin N; Kramkimel N; Guégan S
Melanoma Res; 2020 Jun; 30(3):317-320. PubMed ID: 32053122
[TBL] [Abstract][Full Text] [Related]
22. Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy.
Uribe P; Anforth RM; Kefford RF; Fernandez-Peñas P
Melanoma Res; 2014 Oct; 24(5):501-3. PubMed ID: 24922191
[TBL] [Abstract][Full Text] [Related]
23. Fatherhood during dabrafenib and trametinib therapy for metastatic melanoma.
Cocorocchio E; Pala L; Battaglia A; Gandini S; Peccatori FA; Ferrucci PF
Acta Oncol; 2018 Aug; 57(8):1131-1133. PubMed ID: 29526130
[No Abstract] [Full Text] [Related]
24. Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma.
Park JJ; Hawryluk EB; Tahan SR; Flaherty K; Kim CC
JAMA Dermatol; 2014 Mar; 150(3):307-11. PubMed ID: 24352115
[TBL] [Abstract][Full Text] [Related]
25. Facing the challenges of new melanoma-targeted therapies: Treatment of severe fevers associated with dabrafenib/trametinib combination therapy.
Lindsay JN; Barras M
J Oncol Pharm Pract; 2015 Aug; 21(4):293-5. PubMed ID: 24664475
[TBL] [Abstract][Full Text] [Related]
26. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
Dummer R; Lebbé C; Atkinson V; Mandalà M; Nathan PD; Arance A; Richtig E; Yamazaki N; Robert C; Schadendorf D; Tawbi HA; Ascierto PA; Ribas A; Flaherty KT; Pakhle N; Campbell CD; Gusenleitner D; Masood A; Brase JC; Gasal E; Long GV
Nat Med; 2020 Oct; 26(10):1557-1563. PubMed ID: 33020648
[TBL] [Abstract][Full Text] [Related]
27. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.
Johnson DB; Flaherty KT; Weber JS; Infante JR; Kim KB; Kefford RF; Hamid O; Schuchter L; Cebon J; Sharfman WH; McWilliams RR; Sznol M; Lawrence DP; Gibney GT; Burris HA; Falchook GS; Algazi A; Lewis K; Long GV; Patel K; Ibrahim N; Sun P; Little S; Cunningham E; Sosman JA; Daud A; Gonzalez R
J Clin Oncol; 2014 Nov; 32(33):3697-704. PubMed ID: 25287827
[TBL] [Abstract][Full Text] [Related]
28. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
Sloot S; Zager JS; Kudchadkar RR; Messina JL; Benedict JJ; Gonzalez RJ; DeConti R; Turner LM; McCardle T; Smalley KS; Weber JS; Sondak VK; Gibney GT
Melanoma Res; 2016 Feb; 26(1):83-7. PubMed ID: 26731560
[TBL] [Abstract][Full Text] [Related]
29. Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II).
Atkinson V; Sandhu S; Hospers G; Long GV; Aglietta M; Ferrucci PF; Tulyte S; Cappellini GCA; Soriano V; Ali S; Poprach A; Cesas A; Rodriguez-Abreu D; Lau M; de Jong E; Legenne P; Stein D; King B; van Thienen JV
Melanoma Res; 2020 Jun; 30(3):261-267. PubMed ID: 31895752
[TBL] [Abstract][Full Text] [Related]
30. Adverse Event Management in Patients with
Chalmers A; Cannon L; Akerley W
Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
[TBL] [Abstract][Full Text] [Related]
31. Real-world efficacy and safety data for dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced melanoma.
Takahashi A; Namikawa K; Nakano E; Yamazaki N
J Dermatol; 2020 Mar; 47(3):257-264. PubMed ID: 31876308
[TBL] [Abstract][Full Text] [Related]
32. Dabrafenib- and trametinib-associated glomerular toxicity: A case report.
Jo E; Rhee H
Medicine (Baltimore); 2022 Jan; 101(1):e28485. PubMed ID: 35029901
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
[TBL] [Abstract][Full Text] [Related]
34. Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response.
Gonzalez-Cao M; Boada A; Teixidó C; Fernandez-Figueras MT; Mayo C; Tresserra F; Bustamante J; Viteri S; Puertas E; Santarpia M; Riso A; Barron F; Karachaliou N; Rosell R
Oncotarget; 2016 Aug; 7(35):56619-56627. PubMed ID: 27447748
[TBL] [Abstract][Full Text] [Related]
35. Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor.
Galliker NA; Murer C; Kamarashev J; Dummer R; Goldinger SM
Eur J Dermatol; 2015 Apr; 25(2):177-80. PubMed ID: 25788221
[TBL] [Abstract][Full Text] [Related]
36. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
[TBL] [Abstract][Full Text] [Related]
37. Success of rechallenging dabrafenib and trametinib combination therapy after trametinib-induced rhabdomyolysis: a case report.
Muto Y; Ng W; Namikawa K; Takahashi A; Tsutsumida A; Nishida M; Yamazaki N
Melanoma Res; 2018 Apr; 28(2):151-154. PubMed ID: 29356791
[TBL] [Abstract][Full Text] [Related]
38. Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma.
Dimou A; Barron G; Merrick DT; Kolfenbach J; Doebele RC
BMC Cancer; 2020 Mar; 20(1):177. PubMed ID: 32131760
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
[TBL] [Abstract][Full Text] [Related]
40. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected
Hauschild A; Dummer R; Schadendorf D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Lesimple T; Plummer R; Dasgupta K; Haas T; Shilkrut M; Gasal E; Kefford R; Kirkwood JM; Long GV
J Clin Oncol; 2018 Dec; 36(35):3441-3449. PubMed ID: 30343620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
